Public Health Threats & Emergencies Act
Sens. Frist (R-Tenn.) and Kennedy (D-Mass.) introduce legislation (S 2731) June 14 addressing issues of public health, antimicrobial resistance and bioterrorism. Among the bill's provisions is the establishment of an Antimicrobial Resistance Task Force with representatives of federal agencies, public health groups, drug manufacturers and medical societies to advise HHS on combating antimicrobial resistance. The bill also directs NIH to support R&D for drugs to combat resistant pathogens and sequencing of the genomes of priority pathogens
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth